Fig. 4.

Effects on lymphocyte markers in vivo. B16 cells were implanted s.c. on day 1. Beginning on day 10, mice were treated with decitabine (DAC), IL-2, and/or ODN1826 (ODN) for 2 weeks. A group of mice was not treated. Tumor, lymph nodes, and spleens were harvested on day 24. Mouse lymphokine (a) and lymphocyte transcription factors (b) were assessed by qRT-PCR and compared to the group not treated. Data represent mean RQ, n = 3 mice per group. Mean RQ changes >0.5 log (dotted line) were considered significant. * mean RQ changes >0.5 log compared to without DAC